Clinical Trial Update: Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating whether changes in circulating tumor DNA predict response in patients with esophageal cancer treated with durvalumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Simon C Pacey, MD | Conditions: Oesophageal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING